ORCA – Online Research @ Cardiff



This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/119564/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Twohig, Jason P., Cardus Figueras, Ana, Andrews, Robert, Wiede, Florian, Cossins, Benjamin C., Derrac Soria, Alicia, Lewis, Myles J., Townsend, Michael J., Millrine, David, Li, Jasmine, Hill, David G., Uceda Fernandez, Javier, Liu, Xiao, Szomolay, Barbara, Pepper, Christopher J., Taylor, Philip R., Pitzalis, Costantino, Tiganis, Tony, Williams, Nigel M., Jones, Gareth W. and Jones, Simon A. 2019. Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. Nature Immunology 20, pp. 458-470. 10.1038/s41590-019-0350-0

Publishers page: https://doi.org/10.1038/s41590-019-0350-0

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 Activation of naïve CD4⁺ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in 2 memory CD4⁺ T cells 3 Jason P. Twohig^{1,2#}, Ana Cardus Figueras^{1,2#}, Robert Andrews², Florian Wiede^{3,4}, Benjamin C. Cossins^{1,2}, 4 5 Alicia Derrac Soria^{1,2}, Myles J. Lewis⁵, Michael J. Townsend⁶, David Millrine^{1,2}, Jasmine Li^{3,7}, David G. Hill^{1,2}, Javier Uceda Fernandez^{1,2,∞}, Xiao Liu^{1,2}, Barbara Szomolay^{1,2}, Christopher J. Pepper^{8,9}, Philip R. 6 7 Taylor^{1,2}, Costantino Pitzalis⁵, Tony Tiganis^{3,4}, Nigel M. Williams¹⁰, Gareth W. Jones^{1,2,11} & Simon A. 8 Jones^{1,2*} 9 10 Affiliations: 11 1. Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK 12 2. Systems Immunity University Research Institute, Cardiff University, Cardiff, Wales, UK 13 3. Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia 14 4. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, 15 Australia 16 5. Centre for Experimental Medicine & Rheumatology, William Harvey research Institute, Queen Mary's 17 School of Medicine & Dentistry, London, UK 18 6. ITGR Diagnostics Discovery, Genentech Research & Early Development, 1 DNA Way, South San 19 Francisco, CA94080, USA 20 7. Department of Microbiology, Monash University, Clayton, Victoria 3800, Australia 21 8. Division of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, Wales, UK 22 9. Brighton and Sussex Medical School, University of Sussex, Brighton, UK 23 10. Division of Psychological Medicine & Clinical Neuroscience, School of Medicine, Cardiff University, 24 Cardiff, Wales, UK. 25 11. School of Cellular and Molecular Medicine, Biomedical Sciences Building, University Walk, University 26 of Bristol, Bristol, UK 27 28 [#]JPT and ACF contributed equally to the manuscript; \degree JUF deceased 29th August 2018. 29 30 *Corresponding author: 31 Professor Simon A. Jones, 32 Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, 33 Wales, UK. 34 Tel: +44 29 2068 7325; Fax: +44 29 2068 7303; E-mail: JonesSA@cf.ac.uk

35 ABSTRACT

- 36 The cytokine IL-6 controls the survival, proliferation and effector characteristics of lymphocytes through
- 37 activation of the transcription factors STAT1 and STAT3. While STAT3 activity is an ever-present feature
- 38 of IL-6 signaling in CD4⁺ T cells, prior T-cell receptor activation limits the IL-6 control of STAT1 in effector
- 39 and memory populations. Here we show that STAT1 phosphorylation in response to IL-6 was regulated
- 40 by protein tyrosine phosphatases (PTPN2, PTPN22) expressed in response to the activation of naïve CD4⁺
- 41 T cells. Transcriptomic and chromatin immunoprecipitation-sequencing of IL-6 responses in naïve and
- 42 effector memory CD4⁺ T cells showed how the suppression of STAT1 activation shaped the functional
- 43 identity and effector characteristics of memory CD4⁺ T cells. Thus, protein tyrosine phosphatases induced
- 44 by activation of naïve T cells determined the way activated or memory CD4⁺ T cells sensed and
- 45 interpreted cytokine signals.

Naïve, activated and memory T cells display differences in their ability to respond to antigen. These 46 47 include changes in proliferation, survival, sensitivity to antigen, dependence on co-stimulatory signals 48 and alterations in T cell homing¹. Cytokines responsible for the control of these activities often signal 49 through receptor-associated Janus kinases (Jak proteins) that regulate cytoplasmic transcription factors 50 termed signal transducers and activators of transcription (STAT)². Thus, the Jak-STAT pathway senses and 51 interprets environmental signals essential for proliferation and functional identity². Here, we examined 52 whether cytokine cues delivered by the Jak-STAT pathway can be adapted to fine-tune the effector 53 properties of individual CD4⁺ T cell subsets. 54 Studies of infection, inflammation, autoimmunity and cancer demonstrate that the cytokine IL-6 is

55 essential for the generation of adaptive immunity³. Activities include the maturation and maintenance of

antibody secreting B cells, and responses that shape the effector characteristics of CD4⁺ T helper (T_{H})

57 cells³. In this regard, mice lacking IL-6 often show deficiencies in T cell effector function and memory

recall^{4, 5, 6, 7, 8, 9}. Studies also suggest that CD4⁺ T cells display differences in IL-6 responsiveness that may

reflect the activation status of the T cell^{7, 10, 11, 12}. How these differences arise is currently unclear.

60 The receptor complex responsible for IL-6 signaling consists of a type-1 cytokine receptor (IL-6R, CD126)

61 and a signal-transducing β-receptor (gp130, CD130) subunit³. IL-6R is shed in response to CD4⁺ T cell

62 activation, and inflammatory T cells from sites of disease often display low IL-6R expression^{7, 10, 12, 13, 14, 15,}

63 ^{16, 17}. IL-6 activates the latent transcription factors STAT1 and STAT3³. IL-6 control of STAT3 is essential for

64 T cell recruitment and survival and the maintenance of activated T cells within inflamed tissues^{11, 14, 16}.

65 These STAT3-driven responses include the transactivation of anti-apoptotic regulators and genes that

66 determine the effector or regulatory characteristic of CD4⁺ T cells^{3, 11, 18}. In contrast, IL-6 activation of

67 STAT1 plays a more regulatory role and often determines the transcriptional output of STAT3^{18, 19, 20, 21}.

68 These studies illustrate a complex interplay between STAT1 and STAT3, and emphasize how STAT1

69 signaling may shape the biological properties of IL-6^{18, 20, 21, 22, 23, 24}. Significantly, CD4⁺ T cell activation has

been shown to alter IL-6 signaling through STAT1^{9, 11}. Here we show that STAT1 phosphorylation in

response to IL-6 is suppressed in activated and memory CD4⁺T cells and identified protein tyrosine

72 phosphatases as regulators of STAT1 activity. Our data further showed how this re-programming

73 mechanism may influence the way effector memory CD4⁺ T cells sense and interpret IL-6 signals in

74 disease.

75 **RESULTS**

76 Infiltrating synovial CD4⁺ T cells have altered IL-6-mediated STAT1 activation

- 77 Previous studies suggest that CD4⁺ T cell activation alters cytokine signaling through the Jak-STAT
- pathway^{4, 9, 11}. To further these findings we established antigen-induced arthritis (AIA) in C57BI/6 wild-
- type mice through immunization with methylated BSA (mBSA). Histological joint sections from day 10 of
- 80 AIA were evaluated for tyrosine phosphorylated STAT1 and STAT3 (hereafter pY-STAT1 and pY-STAT3)
- using immunofluorescence (Fig. 1a). While pY-STAT3 co-localized with CD3⁺ T cells, pY-STAT1 showed
- 82 weak co-localization with the CD3 stain (Fig. 1a). To verify these observations, CD4⁺ T cells were isolated
- 83 at day 10 of AIA from the inflamed synovium of wild-type mice and stimulated *ex vivo* with IL-6
- 84 (20ng/ml). When compared to IL-6-treated CD4⁺CD25⁻CD44^{lo}CD62L^{hi}CD127^{hi} naïve T cells (T_N cells) from
- 85 the spleen of wild-type mice, intracellular flow cytometry showed that synovial CD4⁺ T cells displayed
- 86 reduced pY-STAT1 staining (Fig. 1b). Both CD4⁺ T cell populations displayed comparable pY-STAT3
- 87 responses to IL-6 (Fig. 1b). To test whether prior antigenic challenge with mBSA restricted the ability of
- 88 IL-6 to signal through STAT1, we extracted total CD4⁺ T cells from the inguinal draining lymph nodes of
- 89 wild-type mice immunized with mBSA, stimulated them *ex vivo* for 30 min with 20ng/ml IL-6 and
- 90 monitored changes in pY-STAT1 and pY-STAT3 by intracellular flow cytometry. When compared to wild-
- 91 type CD4⁺ T cells from the inguinal lymph node of non-challenged mice, CD4⁺ T cells from mBSA-
- 92 immunized mice showed impaired pY-STAT1 detection in response to IL-6 (Fig. 1c). This reduction in
- 93 pY-STAT1 was particularly evident in activated or memory CD4⁺ T cells (Fig. 1c).
- 94 STAT1 is an important determinant of T cell effector function^{20, 21, 22}. We therefore used quantitative PCR
- 95 to evaluate the effector characteristics of CD4⁺ T cells from wild-type mice with AIA. Analysis was
- 96 performed on CD4⁺ T_N cells and CD4⁺CD25⁻CD44^{hi}CD62L^{lo}CD127^{int-hi} effector memory T cells (T_{EM} cells)
- 97 from the inguinal lymph nodes of wild-type mice with AIA. *Ahr*, *Il21*, *Rorgt*, *Il17a*, *Ifng* and *Stat3* were all
- 98 highly expressed in CD4⁺ T_{EM} cells compared to CD4⁺ T_N cells (Fig. 1d). In contrast, the expression of
- 99 Socs3, a negative regulator of Jak-STAT signaling, remained comparable in both CD4⁺ T cell populations
- 100 (Fig. 1d). In addition, intracellular cytokine staining of $CD4^{+}T_{N}$ and $CD4^{+}T_{EM}$ cells showed that $CD4^{+}T_{EM}$
- 101 cells generated increased amounts of IL-21 (Fig. 1e and Supplementary Fig. 1a). Thus, $CD4^{+}T_{N}$ and $CD4^{+}$
- 102 T_{EM} cells showed differences in IL-6 responsiveness.

103 Control of STAT1 activity is not determined by IL-6R signaling in CD4 $^{+}$ T cells

- 104 To determine if T cell subsets display different IL-6 signaling properties, splenic CD4⁺ T_N cells,
- 105 CD4⁺CD25⁻CD44^{hi}CD62L^{hi}CD127^{hi} central memory T cells (T_{CM} cells), CD4⁺CD25⁻CD44^{lo}CD62L^{lo}CD127^{lo-int}
- 106 effector T cells (T_{Eff} cells) and CD4⁺T_{EM} cells were purified from wild-type mice. These populations
- 107 showed differences in IL-6R and gp130 expression, but displayed a similar transient activation of
- 108 pY-STAT3 in response to IL-6 (Fig. 2a and Supplementary Fig. 1b). A strong induction of pY-STAT1 was

109 observed in IL-6-treated CD4⁺ T_N cells, while CD4⁺ T_{CM} , T_{Eff} and T_{EM} cells showed impaired pY-STAT1

110 activation (Fig. 2a). A similar regulation of pY-STAT1 was also observed in human CD4 $^{\scriptscriptstyle +}$ T cells

111 (Supplementary Fig. 1c).

112 Given that activation-induced shedding of IL-6R may affect IL-6 receptor signaling, we investigated the

113 IL-6 control of pY-STAT1 and pY-STAT3 in splenic CD4⁺ T_N, T_{CM}, T_{Eff} and T_{EM} cells from wild-type and *ll6ra^{-/-}*

mice. IL-6 signaling in *ll6ra^{-/-}* CD4⁺T cells was triggered by IL-6 trans-signaling using an IL-6-sIL-6R chimeric

115 fusion protein (HDS)^{7,8}. *Il6ra^{-/-}* CD4⁺ T cells were not activated by IL-6 alone, but responded to an

equimolar concentration of HDS, and all $I/6ra^{-/-}$ CD4⁺ T cells showed increased pY-STAT3 following HDS

stimulation (Fig. 2b). While HDS induced pY-STAT1 in *Il6ra^{-/-}* CD4⁺ T_N cells, changes in pY-STAT1 was not

seen in HDS-treated CD4⁺T_{CM}, T_{Eff} and T_{EM} cells from *ll6ra^{-/-}* mice (Fig. 2b). Thus, the loss of STAT1

signaling in activated CD4⁺ T cells is independent of changes in IL-6R regulation. A similar pattern of

120 pY-STAT1 regulation was noted in wild-type CD4 * T cells stimulated with IL-27 or IFN- γ (Fig. 2c and

121 Supplementary Fig. 2d), suggesting the control of STAT1 phosphorylation was not unique to IL-6.

122 TCR activation regulates IL-6R signaling in CD4⁺ T cells

123 To investigate whether prior TCR engagement contributed to the changes in STAT1 activation in

activated or memory CD4⁺ T cells we compared IL-6 signaling in CD4⁺ T_N cells and CD4⁺ T cells previously

activated with antibodies against CD3 and CD28. Wild-type $CD4^+ T_N$ cells were cultured for 72h with

126 antibodies against CD3 and CD28 followed by a 48h culture in fresh media, in the absence of exogenous

127 stimulation. This rest period restored the surface expression of IL-6R on these TCR-experienced effector-

128 like $CD4^{+}T$ cells (T_{EXP} cells; Supplementary Fig. 2a). While IL-6 stimulation of $CD4^{+}T_{EXP}$ cells induced

129 pY-STAT3, the activation of pY-STAT1 was minimal when compared to the IL-6-dependent induction of

130 pY-STAT1 in CD4⁺ T_N cells (Supplementary Fig. 2b,c), indicating CD4⁺ T cell activation altered the

131 subsequent activation of STAT1 by IL-6.

132 To test if TCR signaling altered the IL-6-induced activation of STAT1, we generated CD4⁺ T_{EXP} cells from

133 wild-type CD4⁺ T_N cells using varying concentrations of co-stimulatory CD3 (0.1-10 μg/ml) and CD28 (0.5-

134 15 μ g/ml) antibodies (Supplementary Fig. 3a) and stimulated the expanded CD4⁺ T_{EXP} cells with IL-6. The

135 IL-6-dependent induction of pY-STAT3 was not affected by differences in antibody concentration.

136 However the suppression of pY-STAT1 in response to IL-6 was sensitive to anti-CD3 antibody treatment

137 with increasing doses of antibody leading to a repression of pY-STAT1 (Supplementary Fig. 3a). Thus, TCR

138 signaling affected the inhibition of pY-STAT1 by IL-6.

139 We next determined whether changes in STAT1 activation altered the transcriptional output of IL-6. CD4⁺

140 T_N, T_{EXP} and T_{EM} cells were stimulated for 6 h with IL-6 followed by transcriptomic analysis. This time point

141 was selected based on the temporal profile of pY-STAT1 and pY-STAT3 detection (Fig. 2a), and the

- 142 optimal expression of STAT-target genes (*Ahr, Bcl3, Bcl6, Kat2b, Il10, Il21, Pim1, Stat3*), as determined by
- 143 Q-PCR (Supplementary Fig. 3b). CD4⁺ T_N, T_{EXP}, and T_{EM} cells expressed a series of genes that were both
- 144 common (e.g., *Socs1*, *Sbno2*, *Bcl6*) and unique (e.g., CD4⁺ $T_N Cxcr1$, *Tnfrsf14*; CD4⁺ $T_{EXP} Gzma$, *Ajuba*;
- 145 CD4⁺ T_{EM} Ahr, Il10, Il21) to all three CD4⁺ T cell populations (Fig. 2d and Supplementary Fig. 3c). The
- 146 number of transcripts enhanced by IL-6 in CD4⁺ T_{EXP} cells (236) was markedly reduced when compared to
- 147 the IL-6-dependent induction of transcripts in CD4⁺ T_N cells (509) (Fig. 2e). The inclusion of anti-
- 148 CD3+CD28 co-stimulatory antibodies further suppressed the number of genes induced by IL-6 in CD4⁺
- 149 T_{EXP} cells (26), indicating the capacity of TCR activation to replace the signal delivered by IL-6 (Fig. 2e and
- 150 Supplementary Fig. 3d). Thus, IL-6 controls very distinct patterns of gene regulation in CD4⁺ T_N, T_{EXP} and
- 151 T_{EM} cells that may shape the functional properties of these CD4⁺ T cells.

152 STAT1 phosphorylation is regulated by PTPN2

153 We next determined whether TCR activation altered the expression of genes linked with IL-6 receptor

- 154 signaling in CD4⁺ T_N, T_{EXP} and T_{EM} cells. No significant differences in the expression of IL-6 receptor
- 155 subunits (Il6ra, Il6st), Janus kinases (Jak1, Jak2, Tyk2), STATs (Stat1, Stat3, Stat5a, Stat5b) and regulators

156 of IL-6 or Jak-STAT signaling (Socs1, Socs3, Pias1, Dusp2, Cish, Arid5a, Arid5b) were observed between

- 157 these CD4⁺ T cells (Supplementary Fig. 4a). Thus, the immediate regulation of STAT1 activity in CD4⁺ T_{FXP}
- 158 cells and CD4⁺ T_{EM} cells was not attributed to changes in the make-up of the IL-6 signaling cascade.

159 To examine how CD4⁺ T cell activation affected STAT1 signaling we assessed IL-6 responses in wild-type 160 CD4⁺ T_N and T_{EM} cells using antibodies for serine phosphorylated STAT1 and STAT3 (hereafter pS-STAT1 161 and pS-STAT3). Intracellular flow cytometry showed that the IL-6 activation of pS-STAT1 and pS-STAT3 162 was comparable in both CD4⁺ T cells (Fig. 3a). However, CD4⁺ T_{EM} cells showed suppressed pY-STAT1 in 163 response to IL-6 (Fig. 3a and Supplementary Fig. 1c). We therefore addressed whether protein 164 phosphatases controlled the tyrosine phosphorylation of STAT1. Treatment of $CD4^{+}T_{N}$ and T_{FM} cells with 165 the protein tyrosine phosphatase inhibitor sodium orthovanadate reversed the loss of pY-STAT1 166 activation in IL-6-stimulated CD4⁺ T_{FM} cells (Fig. 3a). IL-6 control of pY-STAT3 was unaltered by sodium 167 orthovanadate (Fig. 3a). Analysis of Ahr, Il21, Socs3 and Stat3 expression in IL-6-treated CD4⁺ T_{EM} cells 168 showed that the inclusion of sodium orthovanadate reduced expression of *II21* and *Socs3* (Fig. 3b). Thus, 169 protein tyrosine phosphatase activity appears integral to the IL-6 control of STAT1 in CD4⁺ T_{FM} cells.

170 To identify protein tyrosine phosphatases responsible for the regulation of STAT1 in CD4⁺T_{EXP} and T_{EM}

171 cells we compared transcriptomic data from $CD4^{+}T_{N}$, T_{EXP} and T_{EM} cells activated with anti-CD3+CD28 co-

- 172 stimulatory antibodies. Several protein phosphatases were more highly expressed in CD4⁺T_{EXP} and T_{EM}
- 173 cells than $CD4^{+}T_{N}$ cells, and included the protein tyrosine phosphatases *Ptpn2* and *Ptpn22* (Fig. 3c).

174 Flow cytometry showed that PTPN2 was more highly expressed in $CD4^{+}T_{FM}$ cells than $CD4^{+}T_{N}$ cells (Fig. 4a). Il6ra^{-/-} CD4⁺T_{EM} cells had comparable expression of PTPN2 to wild-type CD4⁺T_{EM} cells (Fig. 4b), 175 176 indicating that PTPN2 expression was independent of IL-6 signaling. To confirm the relevance of these 177 findings to pathology we conducted immunohistochemistry of joint tissue from wild-type mice with AIA. 178 Synovial CD3⁺ T cells showed enhanced expression of PTPN2 and low pY-STAT1 staining (Fig. 4c). Similarly, flow cytometry of IL-6-stimulated CD4⁺ T_{EM} cells revealed that PTPN2 expression correlated 179 with suppression of pY-STAT1 (Fig. 4b, Supplementary Fig. 4b). We next investigated IL-6 signaling in 180 $CD4^{+}T_{N}$ and T_{FXP} cells from whole genome C57BI/6 *Ptpn22^{-/-}* mice and *Lck*-Cre *Ptpn2*^{fl/fl} mice, which lack 181 182 PTPN2 in CD4⁺ T cells. As controls we used IL-6-treated CD4⁺ T_N and T_{FXP} cells isolated from C57BI/6 wild-183 type mice (for PTPN22) or C57BI/6 Ptpn2^{fl/fl} littermates. IL-6 activated pY-STAT1 in both Lck-Cre Ptpn2^{fl/fl} 184 and *Ptpn22^{-/-}* CD4⁺ T_{EXP} cells (Fig. 4d). When compared to IL-6 stimulated CD4⁺ T_{EXP} cells from *Lck*-Cre *Ptpn2*^{fl/fl} mice, the recovery of pY-STAT1 activity in IL-6 treated *Ptpn22^{-/-}* CD4⁺T_{FXP} cells was less obvious 185

- 186 (Fig. 4d). This possibly reflected a lower expression of *Ptpn22* in CD4⁺T_{EXP} cells (Fig. 3c). Thus, PTPN2
- 187 acted as a repressor of IL-6-induced STAT1 tyrosine phosphorylation in activated CD4⁺ T cells.
- 188 We next explored whether PTP activity affected the production of IL-17A and IL-21 in CD4⁺T_{EM} cells.
- 189 Intracellular flow cytometry indicated that *Lck*-Cre *Ptpn2*^{fl/fl} and *Ptpn22*^{-/-} CD4⁺T_{EM} cells mice generated
- 190 less IL-17A and IL-21 than CD4⁺ T_{EM} cells from *Ptpn2*^{fl/fl} littermates or wild-type mice (Fig. 4e,
- 191 Supplementary Fig. 4c). Moreover, ImageStream analysis showed the co-localization of PTPN2 with non-
- 192 phosphorylated STAT1 in wild-type $CD4^{+}T_{EM}$ cells (Fig. 4f). Thus, PTPN2, and to a lesser extent PTPN22,
- 193 regulated STAT1 signaling in activated and memory CD4⁺ T cells.

194 T cell activation re-tunes the transcriptional output of IL-6 in CD4 * T_{EM} cells

- 195 Next, we compared the transcriptional output of IL-6 in CD4 $^{+}$ T_N, T_{EXP} and T_{EM} cells. Analysis was confined
- to significantly regulated genes (*p*<0.05) that displayed both a relative signal intensity of >150 and >1.5
- 197 fold alteration in expression. Circos visualization identified a number of genes that were under IL-6
- 198 control in CD4⁺ T_N (225), T_{EXP} (31) and T_{EM} (180) cells (Fig. 5a). Hierarchical clustering and validation of
- selected gene targets identified IL-6 gene signatures that were either common to all three CD4⁺T cells or
- 200 uniquely expressed by a particular population (Supplementary Fig. 3c). Genes regulated by IL-6 in CD4⁺
- 201 T_N , T_{EXP} and T_{EM} cells were mainly STAT3 target genes^{23, 24} and included genes that encoded
- transcriptional regulators (e.g., Bcl3, Bcl6, Etv6), co-repressors (e.g., Sbno2, Muc1) and negative
- 203 regulators (e.g., *Socs3, Pim1, Batf*) of transcription factors such as STAT3, NF-κB and AP1 (Supplementary
- 204 Fig. 3c).
- 205 Next, we conducted a molecular pathway analysis of the transcriptomic data from IL-6-treated CD4 $^{+}T_{N}$,
- 206 T_{EXP} and T_{EM} cells (Fig. 5b). We also mapped these datasets against publicly-available transcriptomic data

from IL-6-stimulated *Stat1^{-/-}* and *Stat3^{-/-}* CD4⁺ T cells (Fig. 5c)²⁰. This analysis identified a series of STAT1-207 208 regulated genes commonly associated with interferon (e.g., Irf8, Gbp2, Gbp5, Gbp6, Stat1, Parp9). In 209 contrast, STAT3-regulated genes displayed greater functional diversity and were implicated in interleukin 210 signaling, immune activation, proliferation, catabolism and metabolism (e.g., Socs3, Bcl3, Il6r, Kat2b) 211 (Fig. 5b,c). This collective approach demonstrated that STAT1 and STAT3 regulated very distinct patterns 212 of gene expression in IL-6 stimulated $CD4^+T_N$, T_{EXP} and T_{EM} cells (Fig. 5b,c). For example, when compared 213 with IL-6 stimulated CD4⁺T_N cells, activation with IL-6 enhanced the expression of genes associated with 214 prolonged lymphocyte survival and memory (e.g., Hmox1, Myc, Cd83), and regulatory (e.g., Lag3, II10, 215 *Foxp3*) or effector (e.g., *Ahr, Il21, Ifng*) characteristics in CD4⁺T_{EM} cells. 216 We next performed ChIP-seq in IL-6-stimulated CD4⁺ T_N and T_{EM} cells. Sequencing peaks displaying a 4-217 fold increase above input (P<0.0001; FDR 0.05) were aligned to the genome and assigned to transcription 218 start sites (TSS), exons and introns (Fig. 6 and Supplementary Fig. 5). Peaks located in undefined 219 intergenic regions were excluded from the analysis. ChIP-seq of IL-6-stimulated CD4⁺ T_N cells identified 220 1625 peaks associated with STAT1 and 602 peaks for STAT3 (Fig. 6a). The number of STAT1 (446) and 221 STAT3 (552) peaks was reduced in $CD4^+T_{EM}$ cells (Fig. 6a). To understand the regulatory properties of 222 STAT1 and STAT3 we first confined our analysis to peaks residing within TSS regions (Fig. 6b and 223 Supplementary Fig. 5). Sequencing peaks that mapped to defined gene promoters were correlated 224 against corresponding transcriptomic data from IL-6-treated CD4⁺T_N and T_{EM} cells (Fig. 6c and 225 Supplementary Fig. 5). STAT1 and STAT3 showed substantially reduced binding to TSS regions in CD4⁺T_{EM} 226 cells compared to CD4⁺T_N cells (Fig. 6b,c,d). Very few genes shared STAT1 and STAT3 binding (e.g., *Stat3*, 227 Stat5b, Icam1, Socs3, Sigirr, and Akt2) (Fig. 6b,d), and these co-regulated genes were largely restricted to 228 CD4⁺T_N cells (Fig 6b,d). Stat3 was the only gene that was bound by both STAT1 and STAT3 in CD4⁺T_{EM} 229 cells (Fig. 6c). To determine the specificity of these DNA-transcription factor interactions we used 230 computational tools to identify consensus DNA motifs for STAT1 and STAT3 binding (Supplementary Fig. 231 5c). Analysis of ChIP-seq datasets from IL-6-treated CD4⁺T_N and T_{FM} cells identified sequences resembling 232 an IFN-regulated STAT responsive element (ISRE; E-value 5.9e-040) for STAT1 binding, and sequences 233 homologous to a gamma-activated sequence (GAS; E-value 1.2e-115) for STAT3 (Supplementary Fig. 5c). 234 We also identified consensus motifs for other transcription factors including SP1 and C2H2 Zn-finger 235 transcription factor proteins (Supplementary Fig. 5c) and ChIP-qPCR showed STAT1 and STAT3 bound to 236 SP1 consensus binding sequences (Supplementary Fig. 5d and Supplementary Table 2). Thus, 237 transcriptional differences between IL-6 stimulated CD4⁺T_N and T_{EM} cells are shaped by STAT1 and STAT3 238 docking to both classical STAT-responsive elements and DNA motifs that suggested a regulatory interplay 239 with other transcription factors in $CD4^{+}T_{N}$ and T_{EM} cells.

240 Genes under IL-6 control in CD4⁺ T_{EM} cells are regulated at distal promoter regions

241 Next we investigated the canonical pathways associated with the genes that were bound with STAT1 or 242 STAT3 in IL-6-treated CD4⁺ T_N and T_{FM} cells. Bioinformatic analysis identified a selective enrichment of 243 genes involved in disease processes, catabolism and cytokine signaling in CD4⁺T_{FM} cells as compared to 244 CD4⁺T_N cells (Supplementary Fig. 6a and Supplementary Table 3). Many of the genes associated with 245 these pathways were distinct from those showing STAT1 or STAT3 binding to TSS (Fig. 6b), suggesting that genes under IL-6 regulation in CD4⁺T_{EM} cells may be controlled by STAT1 and STAT3 binding to distal 246 247 promoter regions. To identify possible mechanisms that may explain this distal regulation we evaluated 248 whether STAT1 and STAT3 peaks aligned with enhancer regions displaying enriched binding of the 249 histone acetyl-transferase P300 (hereafter P300 enhancer elements^{25, 26, 27, 28}). STAT1 and STAT3 ChIP-seq 250 datasets from IL-6-treated CD4⁺T_N or T_{EM} cells were mapped against publicly-available P300 ChIP-seq 251 data from mouse CD4⁺ T cells polarized *in vitro* into $T_{H}1$, $T_{H}2$ or $T_{H}17$ cells²⁸ (Supplementary Fig. 6b and 252 Supplementary Table 4). A combined analysis of IL-6-treated CD4⁺ T_N and T_{FM} cells identified 558 genes 253 that bound P300 in association with either STAT1 or STAT3 (Fig. 7a,b). In IL-6-stimulated CD4⁺T_N and T_{FM} 254 cells we identified 215 genes that displayed alternate binding of STAT1 or STAT3 in CD4⁺T_N and T_{FM} cells 255 (Fig. 7b). These genes were selectively induced or repressed by IL-6 in CD4⁺ T_{EM} cells (Fig. 7b, 256 Supplementary Table 5). Among these, 208 genes aligned with genes bound by P300 in $T_{H}17$ cells²⁸. 257 These included genes linked with proliferation and survival (e.g., Vmp1, Rbpi, Fasl), immune regulation 258 (e.g., Cd200, Cish, Ctla4, Cd69), alternate lineage fates (e.g., Ahr, Batf, Bcl6, Cxcr5, Etv6, Fosl2, Irf4, Stat3) 259 or differences in T cell effector function (e.g., II10, II21, II4ra, II17a, II17ra, II21r) (Supplementary Table 5). 260 This analysis indicated that genes controlled by IL-6 in $CD4^{+}T_{N}$ and T_{EM} cells are associated with P300 261 enhancer elements that are potentially activated or suppressed by changes in the pattern of STAT1 or

262 STAT3 binding.

263 Among the 215 genes regulated by IL-6 in CD4⁺ T_{EM} cells, 80 displayed STAT1 or STAT3 binding in ChIP-seq data from IL-6 activated CD4⁺T_N cells, but not in IL-6 treated CD4⁺T_{EM} cells (Fig. 7c). This suggested that 264 265 the binding of these transcription factors to these sites acted as repressors of gene activation. ChIP-seq 266 analysis of the other 135 genes showed that some form of STAT1 or STAT3 binding to P300 enhancer 267 elements was retained in both IL-6 stimulated $CD4^{+}T_{N}$ and T_{FM} cells (Fig. 7c and Supplementary Fig. 6b). 268 These included II10, II21, II21r, Bcl3, Batf, Junb, Socs1 and Cd274 (Fig.7c). Circos visualization illustrated 269 how the binding of STAT1 and STAT3 to these promoters differed between IL-6 stimulated $CD4^+T_N$ and 270 T_{EM} cells (Fig. 7c). We identified 5 discrete patterns of STAT1 and STAT3 binding – pattern 1 (CD4⁺T_N cells: 271 no STAT binding; T_{EM} cells: STAT1), pattern 2 (CD4⁺T_N cells: STAT1, STAT3; T_{EM} cells: STAT3), pattern 3 272 (CD4⁺T_N cells: STAT3; T_{FM} cells: STAT3), pattern 4 (CD4⁺T_N cells: STAT1; T_{FM} cells: STAT3) and pattern 5 273 (CD4⁺T_N cells: no STAT binding; T_{EM} cells: STAT3) (Fig.7d). Computational analysis of the genes affiliated 274 to each pattern revealed links with the cytokine control of T cell proliferation, differentiation and survival 275 (Fig. 7d, Supplementary Fig. 6b and Supplementary Table 6). This was particularly apparent in pattern 2,

276 and to a lesser extent, pattern 3 and 5. Promoter regions assigned to pattern 2 displayed binding of 277 STAT1 and STAT3 in IL-6 stimulated CD4⁺T_N cells, but showed a loss of STAT1 in IL-6 activated CD4⁺T_{FM} 278 cells. Genes identified with this form of STAT regulation included Junb, Il4ra, Cd274 and Socs1 (Fig.7c and 279 Supplementary Fig.6b) and suggested a potential link to the PTPN2-regulated of pY-STAT1. We therefore 280 conducted a ChIP-qPCR analysis of STAT1 binding to the promoters of Junb, Il4ra, Cd274 and Socs1 in IL-6-stimulated Lck-Cre *Ptpn2^{fl/fl}* and *Ptpn2^{fl/fl}* CD4⁺T_{EM} cells. STAT1 binding to these promoters was 281 specifically enriched in DNA samples from Lck-Cre *Ptpn2*^{fl/fl}CD4⁺ T_{EM} cells as compared to control *Ptpn2*^{fl/fl} 282 283 CD4⁺T_{EM} cells (Fig. 7e). In contrast, the binding of STAT1 to the TSS regions of *Stat3* and *Irf1* remained 284 unaltered, and DNA samples from Lck-Cre *Ptpn2^{fl/fl}*CD4⁺ T_{EM} cells and control *Ptpn2^{fl/fl}* CD4⁺ T_{EM} cells 285 showed similar enrichment for STAT1 (Fig. 7e). Thus, PTPN2 activity determined STAT1 binding to specific 286 gene promoter regions in IL-6 activated CD4⁺T_{EM} cells.

287 PTPN2 correlates with indices of synovial pathology in rheumatoid arthritis patients

288 Many of the genes identified in IL-6 stimulated CD4⁺T_{EM} cells contribute to the generation and 289 maintenance of effector T cells associated with autoimmunity (Supplementary Table 6). We therefore 290 investigated the relationship between PTPN2 and PTPN22 and these IL-6-regulated genes in RNA-seq 291 datasets from synovial tissues biopsies of 87 patients with rheumatoid arthritis. Expression of PTPN2 and 292 PTPN22 in these biopsy samples was compared against corresponding histological staining of the 293 inflamed synovium for the lymphocyte markers CD3 and CD20 by immunohistochemistry. Analysis 294 revealed a close correlation between PTPN2 and CD3 and CD20 (Fig 8a). This association was particularly 295 evident in synovial biopsies displaying evidence of ectopic lymphoid-like structures (lymphoid-rich) and 296 synovitis with a prominent mononuclear cell infiltrate (myeloid-rich) (Fig. 8b)²⁹. In contrast, PTPN22 297 displayed a more uniform pattern of expression within the inflamed synovium and showed no 298 correlation with lymphocyte markers or the type of synovial pathology (Fig. 8a,b). To establish a possible 299 link between PTPN2 and the synovial expression of genes controlled by IL-6 in activated or memory CD4⁺ 300 T cells PTPN2 was compared against the synovial expression of IL21, IL17A, CD274 and SOCS1. Analysis of 301 synovial RNA-seq datasets showed a correlation between PTPN2 and IL21, IL17A, CD274 and SOCS1 (Fig. 302 8c). This relationship was particularly evident in both lymphoid-rich and myeloid-rich synovitis (Fig. 8c). 303 No clear correlation was observed between PTPN22 and these inflammatory markers (Fig. 8c). Thus, in 304 human synovial pathology, PTPN2 associates with the involvement of lymphocytes in the disease process 305 and corresponds with the expression of several inflammatory mediators linked to the regulation of 306 STAT1 by PTP enzymes.

307 Discussion

Through analysis of Jak-STAT signalling in $CD4^{+}T_{N}$ and T_{EM} cells we identified that protein tyrosine phosphatases induced as a response to $CD4^{+}T_{N}$ cell activation altered the transcriptional output of IL-6 in $CD4^{+}T_{EM}$ cells. Our investigation showed that inhibition of STAT1 phosphorylation by PTPN2 affected the expression of certain STAT-regulated target genes in activated or memory $CD4^{+}T$ cells. Thus, protein tyrosine phosphatases have the capacity to modify the way particular T cell subsets sense and interpret common cytokine cues. Whilst the study focussed on the biology of IL-6, this mechanism may also shape the transcriptional output of other lymphokines in $CD4^{+}T$ cells.

- 315 Protein phosphatases including dual specificity protein phosphatases (DUSP) and protein tyrosine
- 316 phosphatases (PTP) can regulate Jak-STAT signaling^{30, 31}. For example, PTPN2 and PTPN11 control the
- 317 phosphorylation of STAT1 in fibroblasts^{32, 33}. We showed that protein tyrosine phosphatases restrained
- 318 IL-6 signaling through STAT1 in activated and memory CD4⁺ T cells. Transcriptional profiling of PTP
- 319 expression in CD4⁺ T cells identified several candidate enzymes that were induced following CD4⁺ T_N
- 320 activation, including PTPN2, PTPN22 and DUSP2. Because DUSP2 inhibits signaling through STAT3 and
- 321 restricts T_H17 differentiation³⁰, we assessed whether PTPN2 and PTPN22 affected STAT1
- 322 phosphorylation. PTPN2 and PTPN22 inhibited STAT1 activity, but had a less obvious impact on STAT3
- 323 activity. This observation might indicate a physical interaction between these PTP and STAT1.

324 PTPN2 and PTPN22 control various lymphocyte responses, and individuals with genetic polymorphisms 325 in PTPN2 or PTPN22 frequently show increased susceptibility to autoimmune disease^{34, 35}. The ability of 326 PTPN2 and PTPN22 to control Jak-STAT signaling may contribute to these outcomes through the control 327 of immune activation, tolerance and autoimmunity. Our data showed that synovial PTPN2 was highly 328 expressed in lymphoid-rich synovitis. This form of joint pathology is defined by the presence of functional ectopic lymphoid aggregates within the inflamed synovium³⁶. Significantly, PTPN2 has been 329 linked with the regulation of follicular T_H cells and the activation of T and B cell responses^{37, 38, 39, 40}. Our 330 331 investigation showed that PTPN2 controlled the expression of genes commonly associated with ectopic 332 lymphoid-like structures. For example, PTPN2-control of STAT1 phosphorylation was shown to affect the 333 transactivation of inflammatory cytokines (e.g., IL-17A, IL-21), transcription factors (e.g., Bcl6), immune 334 checkpoint regulators (e.g., CD274) and homeostatic chemokine receptors (e.g., CXCR4, CXCR5) involved 335 in the activity or spatial organization of lymphoid aggregates³⁶. The gene signature identified through our 336 screen may therefore predict the efficacy of adoptive immunotherapy and vaccination strategies, or 337 response to biological drug therapies.

338 ChIP-seq of STAT1 and STAT3 in IL-6-treated CD4⁺ T_N and T_{EM} cells showed that both transcription factors 339 bound to consensus motifs for STAT proteins (e.g., ISRE, GAS), and sequences specific for other

transcription factors (e.g., SP1-like proteins)^{41, 42, 43, 44}. While the binding of STATs to these genomic sites 340 341 requires further analysis, our results suggested that the induction of PTPN2 in activated CD4⁺ T cells 342 affected the expression of STAT-regulated genes controlled by P300 enhancer elements. Many of the genes associated with these enhancers were induced by IL-6 in CD4⁺T_{EM} cells and included genes 343 commonly associated with T_H1 , T_H2 , T_H17 or T_{FH} cells^{27, 28}. These activities fit with the capacity of IL-6 to 344 govern CD4⁺T cell memory^{4, 5, 45, 46}. For example, IL-6 renders antigen-specific T cells refractory to 345 346 suppression by regulatory T cells^{56, 57}. However, IL-6 signaling is not critical for the generation or maintenance of CD4⁺ memory cells^{4, 6}. Instead, our data revealed that IL-6 promotes the effector or 347 348 functional characteristics of CD4⁺ T_{EM} cells. This contrasts with the activities of IL-23, which regulates 349 memory recall through the control of cell-cycle progression and proliferation^{7, 47, 48}. Thus, PTPN2 control 350 of STAT1 may support CD4⁺ T cell memory responses by shaping effector memory functions or 351 prolonging lymphocyte survival. Such findings may be relevant to our understanding of how T cells 352 become released from anergy and might explain how T cells become directed down a commitment pathway as a response to specific TCR antigens^{39, 49, 50}. 353

355 Acknowledgements

This manuscript is dedicated in fond memory of J. Uceda Fernandez, a dearly loved friend and colleaguewho was tragically taken from us on the 29th August 2018. Remembered forever.

358 Versus Arthritis (Reference 20770, 19796 awarded to SAJ, NMW & GWJ), Hoffmann la Roche (to SAJ), 359 Kidney Research UK (to SAJ) and the National Health and Medical Research Council of Australia (to TT) 360 provided grant support for this project. GWJ is recipient of a Versus Arthritis Career Development 361 Fellowship (Reference 20305). JUF held a la Caixa PhD Studentship administered through the British 362 Council, and BCC is supported by a PhD studentship from the Systems Immunity University Research 363 Institute at Cardiff. JL is recipient of a Rutherford Fellowship Grant. Analysis of synovial tissues was 364 conducted with support from the Medical Research Council (to CJP; Reference 36661) and the Versus 365 Arthritis funded Experimental Arthritis Treatment Centre (to CJP; Reference 20022). PRT is recipient of a 366 Wellcome Trust Investigator Award (107964/Z/15/Z) and receives funding through the UK Dementia 367 Research Institute. Bioinformatic analysis was developed with support from the Systems Immunity 368 University Research Institute in Cardiff. The authors would like to thank Yuka Kanno, Chris Hunter, 369 Stephen Turner, Toshi Nakayama, Magdalena Czubala, Rachel Errington, Atsushi Onodera, Kiyoshi

370 Hirahara and John O'Shea for their advice, constructive opinions and kind support.

371 Author contributions

- 372 SAJ, GWJ, ACF and JPT wrote the text and prepared the figures for the paper. All authors reviewed and
- approved the final manuscript draft. SAJ, GWJ, TT, NMW, CP, PRT, CJP, JPT, ACF designed the study. BCC,
- 374 RA, ML, MJT, BS, ACF, JPT and NMW conducted bioinformatic, biostatistical, and molecular pathway
- analyses. Laboratory based studies were performed by JPT, ACF, FW, MJT, XL, JUF, ADS, JL, DH and DM.

376 **Competing interests**

- 377 SAJ has received funding support from Hoffman-La Roche, GlaxoSmithKline, Ferring Pharmaceuticals and
- 378 NovImmune SA, and during the last 5 years he has acted as an advisory consultant for Roche, Chugai
- 379 Pharmaceuticals, NovImmune SA, Genentech, Sanofi Regeneron, Johnson & Johnson, Janssen
- 380 Pharmaceuticals, Eleven Biotherapeutics.

381	Refere	References	
382 383 384	1.	MacLeod, M.K., Kappler, J.W. & Marrack, P. Memory CD4 T cells: generation, reactivation and re- assignment. <i>Immunology</i> 130 , 10-15 (2010).	
385 386 387	2.	O'Shea, J.J. <i>et al.</i> The JAK-STAT pathway: impact on human disease and therapeutic intervention. <i>Annu Rev Med</i> 66 , 311-328 (2015).	
388 389 390	3.	Hunter, C.A. & Jones, S.A. IL-6 as a keystone cytokine in health and disease. <i>Nat Immunol</i> 16 , 448-457 (2015).	
391 392 393	4.	Nish, S.A. <i>et al.</i> T cell-intrinsic role of IL-6 signaling in primary and memory responses. <i>Elife</i> 3 , e01949 (2014).	
394 395 396	5.	Longhi, M.P. <i>et al.</i> Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. <i>PLoS Pathog</i> 4 , e1000006 (2008).	
397 398 399	6.	Strutt, T.M. <i>et al.</i> Direct IL-6 Signals Maximize Protective Secondary CD4 T Cell Responses against Influenza. <i>The Journal of Immunology</i> (2016).	
400 401 402	7.	Jones, G.W. <i>et al</i> . Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. <i>J Immunol</i> 184 , 2130-2139 (2010).	
403 404 405	8.	Fielding, C.A. <i>et al.</i> Interleukin-6 signaling drives fibrosis in unresolved inflammation. <i>Immunity</i> 40 , 40-50 (2014).	
406 407 408	9.	Harker, J.A., Lewis, G.M., Mack, L. & Zuniga, E.I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. <i>Science</i> 334 , 825-829 (2011).	
409 410 411	10.	Briso, E.M., Dienz, O. & Rincon, M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. <i>J Immunol</i> 180 , 7102-7106 (2008).	
412 413 414	11.	Teague, T.K. <i>et al.</i> Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling. <i>J Exp Med</i> 191 , 915-926 (2000).	
415 416 417	12.	Hong, C. <i>et al.</i> Interleukin-6 expands homeostatic space for peripheral T cells. <i>Cytokine</i> 64 , 532- 540 (2013).	
418 419 420 421	13.	Chtanova, T. <i>et al.</i> Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. <i>J Immunol</i> 175 , 7837-7847 (2005).	
422 423 424	14.	Curnow, S.J. <i>et al.</i> Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. <i>J Immunol</i> 173 , 5290-5297 (2004).	
425 426 427	15.	Nowell, M.A. <i>et al.</i> Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. <i>J Immunol</i> 182 , 613-622 (2009).	
428 429 430 431	16.	Atreya, R. <i>et al.</i> Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. <i>Nat Med</i> 6 , 583-588 (2000).	

432 433 434	17.	Liao, W., Lin, J.X., Wang, L., Li, P. & Leonard, W.J. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. <i>Nat Immunol</i> 12 , 551-559 (2011).
435 436 437	18.	Villarino, A.V., Kanno, Y. & O'Shea, J.J. Mechanisms and consequences of Jak-STAT signaling in the immune system. <i>Nat Immunol</i> 18 , 374-384 (2017).
438 439 440	19.	Costa-Pereira, A.P. <i>et al.</i> Mutational switch of an IL-6 response to an interferon-gamma-like response. <i>Proc Natl Acad Sci U S A</i> 99 , 8043-8047 (2002).
441 442 443	20.	Hirahara, K. <i>et al.</i> Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity. <i>Immunity</i> 42 , 877-889 (2015).
444 445 446	21.	Peters, A. <i>et al.</i> IL-27 Induces Th17 Differentiation in the Absence of STAT1 Signaling. <i>J Immunol</i> 195 , 4144-4153 (2015).
447 448 449	22.	Jones, G.W. <i>et al.</i> Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. <i>Ann Rheum Dis</i> 72 , 1738-1742 (2013).
450 451 452 453	23.	Anderson, A.E. <i>et al.</i> IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis. <i>Ann Rheum Dis</i> 75 , 466-473 (2016).
454 455 456 457	24.	Pratt, A.G. <i>et al.</i> A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. <i>Ann Rheum Dis</i> 71 , 1374-1381 (2012).
458 459 460	25.	Hnisz, D. <i>et al.</i> Super-enhancers in the control of cell identity and disease. <i>Cell</i> 155 , 934-947 (2013).
461 462 463	26.	Whyte, W.A. <i>et al.</i> Master transcription factors and mediator establish super-enhancers at key cell identity genes. <i>Cell</i> 153 , 307-319 (2013).
464 465 466	27.	Vahedi, G. <i>et al.</i> Super-enhancers delineate disease-associated regulatory nodes in T cells. <i>Nature</i> 520 , 558-562 (2015).
467 468 469	28.	Ciofani, M. <i>et al.</i> A validated regulatory network for Th17 cell specification. <i>Cell</i> 151 , 289-303 (2012).
470 471 472	29.	Humby, F. <i>et al.</i> Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT FilterDetermining Validation Requirements. <i>J Rheumatol</i> 43 , 208-213 (2016).
473 474 475	30.	Lu, D. <i>et al.</i> The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates T17 differentiation. <i>Nat Immunol</i> (2015).
476 477 478	31.	Bohmer, F.D. & Friedrich, K. Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT 3 , e28087 (2014).
479 480 481	32.	ten Hoeve, J. <i>et al.</i> Identification of a nuclear Stat1 protein tyrosine phosphatase. <i>Mol Cell Biol</i> 22 , 5662-5668 (2002).
481 482 483 484	33.	Wu, T.R. <i>et al</i> . SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. <i>J Biol Chem</i> 277 , 47572-47580 (2002).

485 486 487	34.	Hinks, A. <i>et al</i> . Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. <i>Arthritis Rheum</i> 52 , 1694-1699 (2005).
488 489 490 491	35.	Sharp, R.C., Abdulrahim, M., Naser, E.S. & Naser, S.A. Genetic Variations of PTPN2 and PTPN22: Role in the Pathogenesis of Type 1 Diabetes and Crohn's Disease. <i>Front Cell Infect Microbiol</i> 5 , 95 (2015).
492 493	36.	Pitzalis, C., Jones, G.W., Bombardieri, M. & Jones, S.A. Ectopic lymphoid-like structures in
494 495		infection, cancer and autoimmunity. Nat Rev Immunol 14, 447-462 (2014).
496 497 498 499	37.	Wiede, F., Sacirbegovic, F., Leong, Y.A., Yu, D. & Tiganis, T. PTPN2-deficiency exacerbates T follicular helper cell and B cell responses and promotes the development of autoimmunity. <i>J Autoimmun</i> 76 , 85-100 (2017).
500 501 502	38.	Wiede, F. <i>et al</i> . T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. <i>J Clin Invest</i> 121 , 4758-4774 (2011).
503 504 505 506	39.	Salmond, R.J., Brownlie, R.J., Morrison, V.L. & Zamoyska, R. The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals. <i>Nat Immunol</i> 15 , 875-883 (2014).
507 508 509	40.	Wiede, F., La Gruta, N.L. & Tiganis, T. PTPN2 attenuates T-cell lymphopenia-induced proliferation. <i>Nat Commun</i> 5 , 3073 (2014).
510 511 512	41.	Look, D.C., Pelletier, M.R., Tidwell, R.M., Roswit, W.T. & Holtzman, M.J. Stat1 depends on transcriptional synergy with Sp1. <i>J Biol Chem</i> 270 , 30264-30267 (1995).
513 514 515	42.	Cantwell, C.A., Sterneck, E. & Johnson, P.F. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. <i>Mol Cell Biol</i> 18 , 2108-2117 (1998).
516 517 518	43.	Zhang, Z., Jones, S., Hagood, J.S., Fuentes, N.L. & Fuller, G.M. STAT3 acts as a co-activator of glucocorticoid receptor signaling. <i>J Biol Chem</i> 272 , 30607-30610 (1997).
519 520 521	44.	Zhu, M., John, S., Berg, M. & Leonard, W.J. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. <i>Cell</i> 96 , 121-130 (1999).
522 523 524	45.	Kasahara, Y. <i>et al.</i> Role of interleukin 6 for differential responsiveness of naive and memory CD4+ T cells in CD2-mediated activation. <i>J Exp Med</i> 172 , 1419-1424 (1990).
525 526 527	46.	Beagley, K.W. <i>et al.</i> Peyer's patch B cells with memory cell characteristics undergo terminal differentiation within 24 hours in response to interleukin-6. <i>Cytokine</i> 3 , 107-116 (1991).
528 529 530	47.	Lee, Y.K. <i>et al</i> . Late developmental plasticity in the T helper 17 lineage. <i>Immunity</i> 30 , 92-107 (2009).
531 532 533	48.	Haines, C.J. <i>et al.</i> Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. <i>Cell Rep</i> 3 , 1378-1388 (2013).
534 535 536	49.	Mohrs, M., Lacy, D.A. & Locksley, R.M. Stat signals release activated naive Th cells from an an anergic checkpoint. <i>J Immunol</i> 170 , 1870-1876 (2003).

- 53750.van Panhuys, N., Klauschen, F. & Germain, R.N. T-cell-receptor-dependent signal intensity538dominantly controls CD4(+) T cell polarization In Vivo. Immunity **41**, 63-74 (2014).
- 539

540 Figure Legends-

541 Figure 1. Infiltrating T-cells showed impaired STAT1 activity in response to arthritis induction. (a) 542 Representative H&E staining of knee joints at day 10 post disease induction (antigen-induced arthritis, 543 AIA) (bar: 500µm); boxed area shows the location of the immunofluorescence. Representative 544 immunofluorescence with antibodies against CD3 (red), pY-STAT1 or pY-STAT3 (green) is shown together 545 with DAPI counterstaining (blue) (bar: 100μ m). Graph shows the proportion of CD3⁺ T cells displaying 546 either pY-STAT1 or pY-STAT3 (n=3). (b) Phosphorylation of STAT1 and STAT3 by flow cytometry of 547 infiltrating synovial CD4⁺T cells during AIA after stimulation with 20ng/ml IL-6 compare to CD4⁺T_N cells. 548 (c) Representative flow cytometry of pY-STAT1 and pY-STAT3 in CD4⁺ T cells extracted from inguinal 549 lymph nodes of mBSA challenged (n=4) and non-challenged mice (control) (n=3) following stimulation 550 with 20ng/ml IL-6 for 30 min. Graphs show quantification of pY-STAT1 and pY-STAT3 activity in CD4⁺ T_N 551 and CD4⁺ T_{EM} cells (n=4). (d) Quantitative PCR of Ahr, Ifng, Il17a, Il21, Rorc, Socs3 and Stat3 in CD4⁺ T_N 552 (n=4) and CD4⁺ T_{EM} cells (n=2) extracted from inguinal lymph nodes of mBSA challenged mice. (e) 553 Intracellular flow cytometry analysis of IL-21 production in CD4⁺ T_N and CD4⁺ T_{FM} cells extracted from 554 inguinal lymph nodes after 4 hours stimulation with PMA, ionomycin and monensin (n=4). Data are 555 representative of three independent experiments (c,e), two independent experiments (a,b) and one 556 experiment involving biological replicates (d). ****P<0.0001, **P<0.01, *P<0.05 (Two-tailed unpaired 557 Student's t test (a,b,d,e) and one-way ANOVA test with Tukey's multiple comparison test (c). Data are 558 shown as mean \pm s.d.)

559

560 Figure 2. CD4⁺ T cell subsets show different response to IL-6. (a) Representative flow cytometry analysis 561 of STAT1 and STAT3 responses in naïve (T_N), central memory (T_{CM}), effector (T_{Eff}) and effector memory 562 (T_{FM}) CD4⁺ T cells after 30 min IL-6 stimulation (20ng/ml). Numbers indicate the percentage of pY-STAT1 563 or pY-STAT3 staining. Temporal changes in pY-STAT1 and pY-STAT3 are shown for each T cell subset 564 following IL-6 stimulation (n=3). (b) Detection of pY-STAT1 and pY-STAT3 in CD4⁺ T_N, CD4⁺ T_{CM}, CD4⁺ T_{Fff} 565 and CD4⁺ T_{FM} cells from WT and *IL6ra^{-/-}* mice. CD4⁺ T cells were stimulated for 30 min with an equimolar 566 concentration of IL-6 or an IL-6-sIL-6R fusion protein (HDS) (n=3). (c) Intracellular flow cytometry analysis 567 of pY-STAT1 in CD4⁺ T cells following 30 min stimulation with IL-6, IL-27 or IFNγ (20ng/ml) (n=3). (d) 568 Microarray expression data is presented for $CD4^{+}T_{N}$ (n=3), $CD4^{+}T_{FM}$ (n=3), and *in vitro* expanded $CD4^{+}$ 569 effector-like T cells (See Supplementary Fig.2a, CD4⁺ T_{EXP}) (n=4) treated with 20ng/ml IL-6 for 6 hours. 570 Analysis was confined to genes displaying both a relative signal intensity of >150 and >1.5-fold alteration 571 in expression following IL-6 treatment (P<0.05). Heat map is hierarchically clustered based in the relative 572 expression (Z-score) (left panel) or Fold change (right panel). (e) Volcano plots displaying IL-6 regulated 573 gene expression in $CD4^+ T_N$ and $CD4^+ T_{EXP}$ cells stimulated with IL-6 (20ng/ml) or in combination with 574 antibodies against CD3 and CD28. An interactive figure can be found on-line (http://jones-

575 <u>cytokinelab.co.uk/NI2019/figure2d.shtml</u>). Data are representative of two independent experiments
576 (a,c) and one experiment involving biological replicates (b,d,e). ****P*<0.001 **P*<0.05 (Two-tailed unpaired
577 Student's t test (a) and one-way ANOVA with Tukey's multiple comparison test (b,c). Data are shown as
578 mean ± s.e.m).

579

580 Figure 3. Induction of protein tyrosine phosphatases following T-cell activation limits STAT1 signalling. 581 (a) CD4⁺ T_N and CD4⁺ T_{FM} cells were pre-treated for 5 min with 5mM sodium orthovanadate (vanadate) 582 prior to IL-6 (20ng/ml) stimulation for 30 min. Changes in pY-STAT1 and pY-STAT3 activity were 583 monitored by intracellular flow cytometry (MFI). A comparable analysis of pS-STAT1 and pS-STAT3 is 584 shown as a control (n=3). (b) Quantitative PCR for Ahr, Il21, Stat3 and Socs3 after vanadate pre-585 treatment and 20ng/ml IL-6 stimulation in CD4⁺ T_{EM} cells (n=3). (c) Heatmap analysis of Affymetrix 586 transcriptomic data identifies the top 20 genes (P<0.05; relative signal intensity of >150; 1.5-fold 587 alteration) associated with protein tyrosine phosphatase enzyme family. Data is presented as a 588 hierarchical cluster using the average linkage method (row 1-pearson rank correlation). Data are 589 representative of two independent experiment (a,b) and one experiment involving biological replicates 590 (c). ***P<0.001; ** P<0.01 (one-way ANOVA with Tukey's multiple comparison test (a) and two-way 591 ANOVA with Sidak multiple comparison test (b). Data are shown as mean \pm s.e.m (a) and mean \pm s.d (b).

592

593 **Figure 4. STAT1 activity is regulated by PTPN2.** (a) Representative histogram of PTPN2 staining in CD4⁺ 594 T_N and CD4⁺ T_{FM} cells by flow cytometry. (b) Flow cytometry analysis of STAT1 phosphorylation and 595 PTPN2 expression in CD4⁺ T_N and CD4⁺ T_{EM} cells analyzed 30 min after stimulation with 20 ng/ml IL-6. (c) 596 Immunohistochemistry of the inflamed synovium from wild-type mice with antigen-induced arthritis 597 (day-10 post disease induction) in tissue sections stained with antibodies against CD3, Ptpn2 and 598 pY-STAT1. Scale bar, 100µm (left panel) and 200µm (right panel). (d) Analysis of pY-STAT1 and pY-STAT3 in CD4⁺ T_N and CD4⁺ T_{FXP} cells derived from $Ptpn2^{fl/fl}$, Lck-Cre $Ptpn2^{fl/fl}$ (left panel) or wild-type and 599 *Ptpn22^{-/-}* mice (right panel) (n=4) exposed to IL-6 (20 ng/ml) for 30 min in combination with antibodies 600 601 against CD3 and CD28. Fold change relative to the untreated controls are compared. (e) IL-21 and IL-17A guantification by flow cytometry in CD4⁺ T_{FM} cells from $Ptpn2^{fl/fl}$ and Lck-Cre $Ptpn2^{fl/fl}$ mice (n=3). (f) 602 603 ImageStream analysis of STAT1 and PTPN2 localization in CD4⁺ T_N and CD4⁺ T_{FM} cells stained with 604 antibodies against STAT1, pY-STAT1, PTPN2 and CD4. Data are representative of three independent 605 experiments (a,b), two independent experiments (f) and one experiment involving biological replicates 606 (c,d,e). ****P<0.0001; *** P<0.001 (One-way ANOVA with Tukey's multiple comparison test (d) and 607 Two-tailed unpaired Student's test (e). Data are shown as mean \pm s.d.).

609 Figure 5. Transcriptomic analysis of IL-6 responses in CD4⁺ T cells. (a) Circos visualisation details the IL-6 610 regulated gene changes in CD4⁺ T_N and CD4⁺ T_{EXP} cells (See Supplemental Figure-2), and ex vivo sorted 611 $CD4^{+}T_{FM}$ cells. Total number of IL-6 regulated genes is presented in parenthesis for each population (P< 612 0.05, Chip Intensity 150+, and > 1.5-fold change). Lines coloured in red represent up-regulated genes and 613 all down-regulated gene changes are blue. Connecting lines highlight common genes that are IL-6 614 regulated in two or more of the populations. (b) IPA analysis of genes associated with IL-6, STAT1 and 615 STAT3 upstream regulators. Top left heat map shows the predicted activated state (orange) and the 616 predicted inhibited state (blue) of transcription regulators. Upstream regulator analysis for CTLA4 and 617 CD3 are presented as controls. Relative expression heat maps are presented as a hierarchical cluster 618 using the average linkage method (row 1-pearson rank correlation). The differential expression of genes 619 being regulated by IL-6, STAT1 or STAT3 is shown for CD4⁺ T_N, CD4⁺ T_{EXP} and CD4⁺ T_{EM} cells. (c) IL-6 620 regulated gene changes derived from transcriptomic analysis were directly compared with datasets derived from IL-6 stimulated *Stat1^{-/-}* and *Stat3^{-/-}* CD4⁺ T cells (GSE65621). 621 622 623 Figure 6. ChIP-seq analysis of STAT1 and STAT3 binding in IL-6 stimulated CD4⁺ T cells. ChIP-seq was

624 performed on genomic DNA extracted from sorted CD4⁺ T_N and CD4⁺ T_{EM} cells following 1-hour 625 stimulation with IL-6 in presence of antibodies against CD3 and CD28. Peak calling and downstream data 626 processing are described in Materials & Methods. (a) Pie charts show the proportion of peaks associated 627 with STAT1 and STAT3 binding to defined genomic regions. The total number of peaks identified is 628 displayed graphically. All datasets residing outside TSS regions were only included if located to exonic or 629 intronic sites. (b) Analysis of gene clusters regulated by binding STAT1 and STAT3 in TSS promoter 630 regions. The heat map shows the score value for each gene identified with Homer for STAT1 and STAT3 631 ChIP-seq data in $CD4^+ T_N$ (blue) and $CD4^+ T_{EM}$ (red) cells. (c) Comparison of ChIP-seq datasets against 632 Affymetrix gene expression (relative significance; -(log10 (adjusted P-value)). Analysis of STAT1 and 633 STAT3 datasets is shown for $CD4^{+}T_{N}$ (blue) and $CD4^{+}T_{FM}$ (red) subsets. An interactive figure of additional 634 information can be found on-line (http://jones-cytokinelab.co.uk/NI2019/figure6c.shtml) (d) Circos 635 visualization of STAT1 and STAT3 binding to TSS regions of genes under IL-6 regulation in $CD4^+T_N$ and 636 CD4⁺ T_{FM} cells. Connecting lines are color coded to reflect involvement of STAT1 (green), STAT3 (blue) or 637 both STAT1 and STAT3 (orange).

638

Figure 7. IL-6 regulates the interaction of STAT1 and STAT3 with P300 enhancer sites. (a) Circos plot
 shows the co-localisation of STAT1 (blue) and STAT3 (orange) binding to genomic regions sharing P300
 enrichment in CD4⁺ T_N and CD4⁺ T_{EM} cells. The connecting lines show the relationship of STAT1 and STAT3
 binding between CD4⁺ T_N and CD4⁺ T_{EM} cells. P300 ChIP-seq datasets (Accession number GSE40463,
 GSE60482) are derived from T_H1, T_H2 and T_H17 cells. (b) Heat map showing the expression of all IL-6

- 644 regulated genes linked with P300 binding in CD4⁺ T_N and CD4⁺ T_{EM} cells (positioned left). The 645 correspondingly aligned heatmap (positioned right) shows the relationship to P300 sites in T_H1, T_H2 and 646 $T_{\rm H}$ 17 cells and shows the number of clustered P300 sites affiliated to an individual gene (blue=0, 647 yellow=4). Specific examples of individual genes are shown. (c) Circos visualisation of 135 genes that 648 display P300 binding in association with either STAT1 or STAT3 in $CD4^+ T_N$ versus $CD4^+ T_{FM}$ cells. (d) IPA 649 predictions of the five distinct patterns of STAT binding identified from panel c. Hierarchical clustering of 650 canonical pathways was performed using -Log (P-value). Supplemental Table 6 lists the canonical 651 pathways represented in the heatmap. (e) STAT1 binding enrichment quantification by ChIP-qPCR in 652 Ptpn2^{fl/fl} and Lck-Cre:Ptpn2^{fl/fl} CD4⁺ T_{EM} cells (one experiment with pool samples from 12 *Ptpn2*^{fl/fl} and 8 653 *Lck-Cre Ptpn2^{fl/fl}* mice). 654 655 Figure 8. Association of PTPN2 with rheumatoid arthritis. (a) Correlations of PTPN2 and PTPN22 with 656 lymphocyte cell markers CD3 and CD20 (left). (b) Distribution of PTPN2 and PTPN22 in patients stratified 657 according synovial pathology (lymphoid – blue, myeloid – red and fibroid – green) (right). (c) Pearson
- 658 correlations of synovium *PTPN2* and *PTPN22* with inflammatory markers including *IL21*, *IL17A*, *CD274*
- and *SOCS1* in lymphoid (blue), myeloid (red) and fibroid (green) phenotypes. *P* values were adjusted
- 660 using false discovery rate (FDR) correction (Benjamini-Hochberg).
- 661

662 Materials and methods-

- 663 **Recombinant Cytokines-** Recombinant mouse IL-6 (IL-6), IL-27, IL-10, IL-7 and IFNγ were purchased from
- 664 R&D Systems. The IL-6-sIL-6R fusion protein HDS (Mw: 63.5kDa) was expressed in CHO cells and purified
- through a partnership with the CRO Biovian OY (Turku, Finland). HDS was engineered by coupling the
- 666 entire coding sequence (amino acid residues 1-364) for the differentially-spliced variant of human IL-6R
- 667 (containing the unique COOH-terminal amino acid sequence: GSRRRGSCGL) to IL-6 (amino acid residues
- 668 29-212) *via* a flexible glycine-serine rich linker sequence (single amino sequence: GGGGSGGGGSLE)⁸.
- 669 Antibodies- Mouse specific antibodies against CD3ε/γ (17A2; Biolegend), CD4 (RM4-5; eBioscience),
- 670 CD25 (PC61.5; eBioscience), CD44 (IM7; BD Biosciences), CD62L (MEL-14; Life Technologies), CD126
- 671 (D7715A7; eBioscience), CD127 (25-1271-82; eBioscience), βTCR (H57-597), gp130 (125623; R&D
- 672 Systems), IFNγ (XMG1.2; eBioscience), IL-4 (11B11; eBioscience), IL-17A (TC11-18H10.1; Biolegend), IL-21
- 673 (Recombinant mouse IL-21R Fc Chimera protein; R&D and IL-21 receptor antibody; Jackson Immuno
- 674 Research) and PTPN2 (AF1930; R&D) were used. For detection of human antigens, we used antibodies
- 675 specific to CD3 (UCHT1; BioLegend), CD4 (RPA-T4; eBioscience), CD45RA (HI100; BioLegend), CD45RO
- 676 (UCHL1; BioLegend), CD62L (DREG-56; BD Biosciences), CD197 (CCR7; G043H7; BioLegend). Human and
- 677 mouse cross-specific antibodies to pY-STAT1 (pY701; 4a), pY-STAT3 (pY705; 4/P-STAT3), pS-STAT1
- 678 (pS727; K51-856) and pS-STAT3 (pS727, 49/p-Stat3) were from BD Biosciences.

679 Mice- Inbred wild type C57BL/6 male mice were purchased from Charles River UK. C57BL/6 IL-6 receptor 680 deficient mice (*Cd126^{-/-}*) mice have been described previously and were bred under approved UK Home 681 Office guidelines in Cardiff University⁷. *Ptpn2*^{fl/fl}, *Lck-Cre:Ptpn2*^{fl/fl}, and *Ptpn22^{-/-}* mice were bred and 682 housed at the Peter MacCallum Cancer Centre (Melbourne, Australia). All mice were 8-12 weeks of age. For T cell stimulation experiments eight-week-old male *Lck*-Cre;*Ptpn2*^{fl/fl} mice and *Ptpn2*^{fl/fl} littermate 683 controls were used³⁸. All procedures were performed in accordance with the NHMRC Australian Code of 684 685 Practice for the Care and Use of Animals, and approved by the Peter MacCallum Animal Ethics and 686 Experimentation Committee (Ethics number: AEEC 570). Antigen-induced arthritis was performed under 687 the UK Home Office-approved project licences PPL 30/2928 and PB3E4EE13 as previously described⁵¹. 688 Briefly, mice were immunized (s.c.) with 100 µl mBSA (1 mg/ml emulsified in Complete Freund's 689 Adjuvant; CFA) and 160 ng Bordetella pertussis toxin (i.p.) (all from Sigma-Aldrich). Mice were 690 administered with mBSA and CFA (s.c.) one week later. Inflammatory arthritis was triggered 21 days 691 following the initial immunization by intra-articular administration of mBSA (10 μl; 10 mg/ml) into the 692 right knee joint. Animals were monitored daily for wellbeing and clinical signs of arthritis, and killed at 693 indicated time points for evaluation of joint-infiltrating T cells by flow cytometry and

694 immunofluorescence. For flow cytometric analysis of synovial CD4⁺T cells, inflamed synovium was first

dissected and digested in Collagenase type IV (37°C, 1 hour) before passing through a 40μm cell strainer
 to generate single cell suspensions.

697 Human synovial samples- Synovial samples were acquired through a minimally invasive ultrasound-698 guided synovial biopsy (see Reference⁵²) from 87 patients presenting with early rheumatoid arthritis (RA) 699 naïve to therapy from the Pathobiology of Early Arthritis Cohort (PEAC). Ethical approval was granted by 700 the King's College Hospital Research Ethics Committee (REC 05/Q0703/198). Paraffin embedded sections 701 (3µm) of each biopsy was stained with haematoxylin and eosin. Immune cell infiltration was determined 702 in sequentially cut sections by staining for B-cells (CD20), T cells (CD3), macrophages (CD68) and plasma 703 cells (CD138) as previously reported, categorising samples into Lympho-myeloid, Diffuse-Myeloid and 704 Pauci-immune Fibroid pathotypes⁵³.

CD4⁺ T cell cultures- Murine CD4⁺ T cells were enriched by negative magnetic selection (Miltenyi Biotec)
 before purification of naïve (CD4⁺CD25⁻CD44^{lo}CD62L^{hi}CD127^{hi}), central memory
 (CD4⁺CD25⁻CD44^{hi}CD62L^{hi}CD127^{hi}), effector (CD4⁺CD25⁻CD44^{lo}CD62L^{lo}CD127^{lo-int}) or effector memory
 (CD4⁺CD25⁻CD44^{hi}CD62L^{lo}CD127^{int-hi}) T cells using a BD FACS ARIA II (BD Biosciences). T cell subset purity

709 was >98%. Naïve CD4⁺ T cells were cultured in RPMI-1640 supplemented with 10% (v/v) FCS, 2mM L-

710 glutamine, 100U/ml penicillin, 100μg/ml streptomycin, 1mM sodium pyruvate and 50μM 2-

mercaptoethanol. 1 x 10^5 CD4 T cells were activated by plate bound anti-CD3 (1µg/ml; 145-2C11, R&D

512 Systems) and soluble anti-CD28 (5µg/ml; 37.51, eBioscience). Where indicated, CD4⁺ T cells were rested

for 48 hours in the absence of stimulatory antibodies or cytokines (see Supplementary Fig. 2a). CD4⁺ T

cells from the inguinal lymph nodes of mBSA-immunized and non-immunized mice were derived using a

715 CD4⁺ T cell isolation kit (Miltenyi Biotec) and treated with IL-6 for 30 min with anti-CD3/CD28

stimulation. Human peripheral blood mononuclear cells (PBMC) were isolated from fresh whole blood as

previously described⁵⁴. Naïve (CD3⁺CD4⁺CD45RO^{lo}CD62L^{hi}CCR7^{hi}), central memory

718 (CD3⁺CD4⁺CD45RO^{hi}CD62L^{hi}CCR7^{hi}), effector (CD3⁺CD4⁺CD45RO^{lo}CD62L^{lo}CCR7^{lo}) or effector memory

719 (CD3⁺CD4⁺CD45RO^{hi}CD62L^{lo}CCR7^{lo}) CD4⁺ T cells were then purified using a BD FACS ARIA II (BD

720 Biosciences). To investigate the involvement of protein tyrosine phosphatases CD4 T cells were pre-

treated (5 min) with 5mM sodium orthovanadate (New England BioLabs (UK) Ltd) prior to subsequent

722 stimulation.

723 Histological analysis- Formalin-fixed paraffin-embedded knee joints from AIA-challenged mice were

724 prepared for immunofluorescent and immunohistochemical detection of antigens as described

previously⁵¹. For immunofluorescence, sections were rehydrated and antigen retrieval performed in

10mM sodium citrate buffer containing 0.05% (v:v) Tween 20 (95°C, 40 min). Sections were incubated

with 10% (v:v) goat or swine serum appropriate to the secondary antibody. Cells positive for CD3 and

728 intracellular phospho-STAT1 and STAT3 were detected using CD3 (A0452, Dako), and pY-STAT1 (Tyr701; 729 58D6) or pY-STAT3 (Tyr705; D3A7) specific antibodies from Cell Signaling Technologies. For CD3 staining, 730 primary antibody detection was performed using biotinylated swine anti-rabbit IgG (E0431, Dako) with 731 streptavidin-APC (BD Biosciences). For pY-STAT1 and pY-STAT3 detection a secondary rabbit anti-goat 732 IgG Alexa Fluor 488 antibody (Life Technologies) was used. Slides were mounted with Prolong Gold 733 Antifade with DAPI nuclear counterstain (Invitrogen). Images were collected using a Zeiss Apotome 734 microscope and analyzed using ImageJ software. For immunohistochemistry, antigens were detected in 735 paraffin sections using antibodies against CD3 (A0452, Dako), pY-STAT1 (Tyr701; 58D6) and PTPN2 736 (AF1930, R&D Systems). Antigen retrieval was performed as above, and endogenous peroxidase activity 737 blocked using 3% (v:v) H₂O₂. Antibody labelling was detected using biotinylated secondary antibodies 738 (Dako, E0431), the Vectastain ABC kit and diaminobenzidine (Vector Laboratories). Sections were 739 counterstained with haematoxylin. Images were collected using Leica DM 2000 Led and quantification of 740 staining performed using the Leica QWin microscope imaging software.

741 Flow cytometry- Analysis was performed as described previously^{7, 8, 15}. For the intracellular detection of 742 STAT1 and STAT3 phosphorylation, purified $CD4^+$ T cells were fixed in 2% (w:v) paraformaldehyde for 15 743 min at 37°C, followed by permeabilization in 90% (v:v) methanol at -20°C for 3hrs. Cells were stained for 744 CD4 and phosphorylated STAT1, STAT3⁷. To evaluate effector cytokine production, CD4⁺ T cells were 745 stimulated with 50ng PMA (phorbol 12-Myristate 13-Acetate), 500ng ionomycin and 3µM monesin for 4 hours prior to flow cytometric analysis^{7, 8, 15}. Cells were acquired on a CyAn ADP analyzer (Beckman-746 747 Coulter) and analysed using Summit (software v4.3, Beckman-Coulter) or FlowJo 10 (TreeStar). For 748 imaging flow cytometry, cells were resuspended in 100 μ l of PBS and acquired using the ImageStream 749 imaging flow cytometer (Amnis). For co-localization analysis ImageStream software IDEAS (Amnis) was 750 used.

751 RNA purification and Q-PCR- For quantitative real-time PCR (Q-PCR), and Affymetrix gene chip analysis, 752 total RNA was extracted from purified or cultured CD4 T cells using the RNeasy Mini Kit (Qiagen) and 753 QIAshredders (Qiagen). Contaminating genomic DNA was removed by on-column DNase digestion 754 (Qiagen). RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor kit (Life Technologies). Gene expression was determined by Q-PCR^{8, 55} using the 755 756 QuantStudio 12K Flex Real-Time PCR system and the following TagMan probes from Thermofisher: Ahr 757 (Mm00478932 m1), Bcl3 (Mm00504306 m1), Bcl6 (Mm01342164 m1), II10 (Mm00439614 m1), II21 758 (Mm00517640 m1), Irf1 (Mm01288580 m1), Socs3 (Mm00545913 s1), Stat3 (Mm01219775 m1), Pim1 759 (Mm00435712 m1) and Actb (Mm01205647 g1) as a housekeeping gene. Relative mRNA expression 760 was determined by the comparative cycle threshold (CT) method and normalised to the gene Actb.

761 Affymetrix microarray and transcriptomic analysis- Purification of high quality RNA (RNA integrity 762 number >8.5) was confirmed using Agilent RNA Nano microfluidic chips using a 2100 Bioanalyzer 763 Instrument (Agilent Technologies). Expression profiling was performed in triplicate using Affymetrix 764 Mouse GeneChip® 2.0ST microarrays (Affymetrix). Single-stranded cDNA was synthesized using the 765 Ambion[®] WT (Whole Transcript) Expression Kit with the Affymetrix[®] Genechip[®] Poly-A RNA Control Kit 766 and Terminal Labelling kit. Arrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix). Raw 767 Affymetrix data files (CEL files) were imported into an in-house analysis pipeline written in R (version 3.1.1) using Bioconductor packages, namely limma, affy and oligo^{56, 57, 58, 59}. Data were background 768 769 corrected, log2 transformed and quantile normalized using the oligo package (RMA) "best practice". 770 Differentially expressed genes and transcripts were identified using the limma package "best practice" 771 workflow and P-values were corrected by multiple testing using Benjamini-Hochberg (false discovery

772 rate)⁵⁷.

773 Bespoke coding (Perl) (Code available on request) was used to unite data over all conditions. To identify 774 differentially expressed genes over all experiments, we selected the genes that were classified as having 775 altered expression (either decreasing or decreasing) by a difference of 1.5-fold or greater, with a 776 significant value $P \le 0.05$ and a minimal expression value of 150 relative intensity units. Only transcripts 777 fulfilling all these selection criteria in three independent microarray experiments were included in the 778 analysis. Files were also created in the input format required for molecular and pathway analysis using 779 Metacore integrated software suite (Thomson Reuters)⁵⁹ and Ingenuity Pathway Analysis (IPA, 780 http://www.ingenuity.com/products/ipa). Transcriptome matrix visualization and hierarchical clustering 781 were performed using Morpheus software (https://software.broadinstitute.org/morpheus/). Circos plot were obtained using the Circos software (http://circos.ca/software/)⁶⁰. Networks were visualization and 782 783 analysed using the open sourced program Gephi (0.9.1) (https://gephi.org/). Microarray data have been 784 deposited in ArrayExpress under Accession code E-MTAB-7682.

RNA-sequencing- Open access datasets from IL-6 treated Stat1^{-/-} and Stat3^{-/-} T cells (GSE65621) were
 obtained from GEO (https://www.ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house
 bioinformatic pipeline. Briefly, RNA-seq single-end fastq files were mapped to mouse assembly GRCm38
 using STAR⁶¹. Transcript counts were produced with FeatureCounts⁶² and data normalised using the
 Bioconductor package, DeSeq2⁶³ obtaining gene expression values as FPKM (Fragments Per Kilobase
 Million).

For the human samples, RNA from homogenised synovial tissue was extracted in Trizol. 1µg total RNA

792 was used as input material for library preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina).

793 Generated libraries were amplified with 10 cycles of PCR. Library size was confirmed using 2200

794 TapeStation and High Sensitivity D1K screen tape (Agilent Technologies) and concentration was 795 determined by Q-PCR based method using Library quantification kit (KAPA). Libraries were multiplexed 796 (five per lane) and sequenced on Illumina HiSeq2500 (Illumina) to generate 50 million paired-end 75 base 797 pair reads. Transcript abundance was derived using Kallisto v0.43.0 with GENCODE v24/GRCh38 as 798 reference⁶⁴. Transcript abundances were summarised over transcript isoforms using Bioconductor 799 package tximport 1.4.0. Imported abundances were processed using DESeq2 1.14.1 and transformed as 800 regularised log expression (RLE). Statistical analysis of gene-gene correlations was performed using 801 Pearson correlation. P values were adjusted using false discovery rate (FDR) correction (Benjamini-802 Hochberg). RNA-seq data have been deposited in ArrayExpress under Accession code E-MTAB-6141.

803 Chromatin Immunoprecipitation (ChIP)-seq- STAT1 and STAT3 chromatin Immunoprecipitation was 804 performed as previously described²⁰. Briefly, 1×10^7 naïve (T_N) and effector memory (T_{EM}) CD4⁺ T cells 805 were activated for 1h with 20ng/ml IL-6 in the presence of antibodies against CD3 and CD28 (as 806 described earlier). Genomic DNA was extracted, cross-linked and fragmented by sonication prior to 807 overnight incubation with 5ug of anti-STAT1 (sc-592, Santa Cruz Biotechnology) or anti-STAT3 (sc-482, 808 Santa Cruz Biotechnology) antibodies. The quality of the immunoprecipitation was confirmed by ChIP-809 gPCR for Irf1 and Socs3. To minimize systematic biases in the downstream data, an input reference 810 control sample (chromatin taken before ChIP) was used to correct for genomic copy number variations, 811 sonication-induced fragmentation bias, and chromatin accessibility. ChIP-seq libraries for Ion Torrent 812 sequencing were prepared according to manufacturer's instructions (# 4473623, Ion ChIP-Seq Library 813 Preparation on the Ion Proton TM System). Briefly, DNA fragments were end-repaired and ligated to ion-814 compatible adapters. Libraries were amplified and size-selected for insert lengths of approximately 100-250bp. Between 40M to 70M reads were obtained for each sample and mapped to Murine Genome 815 Build GRCm38 (mm10) using the Ion Proton recommended mapper, Bowtie2^{65, 66}. Reads were removed 816 817 where mapping quality was less than q20 (phred score) and peaks called using HOMER (Hypergeometric 818 Optimization of Motif EnRichment). To identify putative peaks in both ChIP and input, we first used 819 HOMER findPeaks with a False Discovery Rate (FDR) value of 0.05. To identify sample peaks in the 820 context of input, we then used HOMER findPeaks with the default parameters (Fold Change > 4-fold, P-821 value < 0.0001). Peaks were visualised using Integrative Genomics Viewer (IGV 2.3.88⁶⁷). Available p300 822 ChIP-seq fastq files from CD4⁺ T cells, T_H1, T_H2 (GSE40463) and T_H17 (GSE60482) were obtained from GEO 823 (https://www.ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house pipeline. Reads were 824 mapped to the same mm10 assembly using BWA. All reads with a mapping quality less than q20 were 825 removed. HOMER isoftware was used to locate P300 enhancer elements (using the Homer option, -style 826 super) and parameters Fold Change > 2-fold, P-value < 0.0001. To align STAT1 or STAT3 peaks with SE 827 regions, overlapping loci identified by STAT1 and STAT3 ChIP-seg and p300 ChIP-seg were identified

- 828 using bedtools (http://bedtools.readthedocs.io/en/latest/)⁶⁸. ChIP-Seq data have been deposited in
- 829 ArrayExpress under Accession code E-MTAB-6273.
- 830 ChIP-qPCR- To validate STAT-binding to promoter regions, Taqman custom assays were designed (see
- 831 Supplementary Table 2 for oligonucleotide primer sequences) and qPCR performed using a QuantStudio
- 832 12K Flex Real-Time PCR System. For analysis of SP1, chromatin immunoprecipitation was conducted as
- 833 previously described using 5ug of SP1 antibody (#17-601, Millipore) or isotype specific IgG control.
- 834 Analysis by qPCR used oligonucleotide primer sequences to the promoter regions of *Irf1*, *Socs3*, *Stat3*,
- 835 Cd274, Il4ra, Junb and Socs1 (Supplementary Table 2). Specific enrichment was normalised by
- 836 subtracting the IgG control values from those derived for the input and antibody specific
- immunoprecipitation samples. Value were expressed as $2^{\Lambda \Delta CT}$.
- 838 **Motif finding-** MEME Suite 4.11.2 software was used to discover *de novo* enriched DNA consensus
- 839 sequences present in peaks identified within the STAT1 or STAT3 ChIP-seq datasets. All sequence
- 840 predictions derived from MEME based on the interaction of known transcription factors with target DNA
- 841 sequences where substantiated using STAMP⁶⁹ (<u>http://benoslab.pitt.edu/stamp/</u>) and JASPAR database
- 842 (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl)⁷⁰.
- 843 Statistics- To determine the statistical significance of differences between data sets, Two-tailed unpaired
- 844 Student's t-test were performed when two populations were compared. One-way ANOVA followed
- 845 Tukey's comparison test was used for multiple comparisons, unless otherwise specified, conducted using
- 846 GraphPad Prism 5 (GraphPad Software). Statistical significance is also highlighted with the following
- 847 notations: *P<0.05; **P<0.01; ***P<0.001, ****P<0.0001. $P \le 0.05$ was considered significantly
- 848 different.
- 849 **Reporting Summary-** Further information on experimental design is available in the *Life Sciences*
- 850 *Reporting Summary* linked to this article.
- 851 Data Availability- Microarray, ChiP-seq and RNA-seq data have been deposited in ArrayExpress under
- Accession code E-MTAB-7682, E-MTAB-6273 and E-MTAB-6141, respectively. Available p300 ChIP-seq
- 853 fastq files from CD4 T cells, Th1, Th2 (GSE40463) and Th17 (GSE60482), and Stat1^{-/-} and Stat3^{-/-} T cells
- 854 (GSE65621) were obtained from GEO (<u>https://www.ncbi.nlm.nih.gov/geo/</u>). Access to interactive data
- 855 sets can be found at <u>www.jones-cytokinelab.co.uk</u> (see relevant *Figure Legends* for additional
- 856 information).

857	References				
858	51.	Jones, G.W. et al. Interleukin-27 inhibits ectopic lymphoid-like structure development in early			
859 860		inflammatory arthritis. J Exp Med 212, 1793-1802 (2015).			
861	52.	Kelly, S. et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for			
862	52.	obtaining high-quality synovial tissue from both large and small joints in early arthritis patients.			
863		Ann Rheum Dis 74 , 611-617 (2015).			
864					
865	53.	Humby, F. et al. Ectopic lymphoid structures support ongoing production of class-switched			
866		autoantibodies in rheumatoid synovium. PLoS medicine 6, e1 (2009).			
867					
868	54.	Jones, G.W. et al. Naive and activated T cells display differential responsiveness to TL1A that			
869		affects Th17 generation, maintenance, and proliferation. FASEB J 25, 409-419 (2011).			
870					
871 872	55.	Greenhill, C.J. <i>et al.</i> Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. <i>Arthritis Res Ther</i> 16 , 419 (2014).			
873		innammatory artificits and joint destruction. Artificits Res Ther 16, 419 (2014).			
874	56.	Gentleman, R.C. et al. Bioconductor: open software development for computational biology and			
875	50.	bioinformatics. <i>Genome Biol</i> 5 , R80 (2004).			
876					
877	57.	Ritchie, M.E. et al. limma powers differential expression analyses for RNA-sequencing and			
878		microarray studies. Nucleic Acids Res 43, e47 (2015).			
879					
880	58.	Gautier, L., Cope, L., Bolstad, B.M. & Irizarry, R.A. affyanalysis of Affymetrix GeneChip data at			
881		the probe level. <i>Bioinformatics</i> 20 , 307-315 (2004).			
882					
883	59.	Carvalho, B.S. & Irizarry, R.A. A framework for oligonucleotide microarray preprocessing.			
884 885		Bioinformatics 26 , 2363-2367 (2010).			
886	60.	Krzywinski, M. et al. Circos: an information aesthetic for comparative genomics. Genome Res 19,			
887	00.	1639-1645 (2009).			
888					
889	61.	Dobin, A. <i>et al.</i> STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> 29 , 15-21 (2013).			
890					
891	62.	Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program for assigning			
892		sequence reads to genomic features. Bioinformatics 30 , 923-930 (2014).			
893					
894	63.	Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-			
895		seq data with DESeq2. Genome Biol 15, 550 (2014).			
896 897	64.	Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq			
898	04.	quantification. Nature biotechnology 34 , 525-527 (2016).			
899					
900	65.	Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357-			
901		359 (2012).			
902					
903	66.	Robertson, G. et al. Genome-wide profiles of STAT1 DNA association using chromatin			
904		immunoprecipitation and massively parallel sequencing. Nat Methods 4, 651-657 (2007).			
905					
906	67.	Robinson, J.T. et al. Integrative genomics viewer. Nature biotechnology 29, 24-26 (2011).			
907	60	Quiplon A.D. & Holl I.M. DEDTooley of avita of utilities for comparing concerts fortunes			
908 909	68.	Quinlan, A.R. & Hall, I.M. BEDTools: a flexible suite of utilities for comparing genomic features. <i>Bioinformatics</i> 26 , 841-842 (2010).			
,0,		$Domjormatics \mathbf{zo}, \mathbf{otr} \mathbf{otr}_{\mathbf{z}} (\mathbf{zoroj}).$			


910


- 911 69. Mahony, S. & Benos, P.V. STAMP: a web tool for exploring DNA-binding motif similarities. *Nucleic*912 *Acids Res* 35, W253-258 (2007).
- 913
 914 70. Mathelier, A. *et al.* JASPAR 2016: a major expansion and update of the open-access database of 915 transcription factor binding profiles. *Nucleic Acids Res* 44, D110-115 (2016).


916


а

b











80-

60-

40

20

0 80-

60-

40

20 0

IL-21 + (%)

IL-17A + (%)

f Ptpn2^{fl/fl} Lck-Cre Ptpn2fl/fl

_


4

2

0

IL-6

-+



4

2

PTPN2 CD4 Merge 0 0 CD4 $^{+}$ T_N cells 1 CD4+ T_{EM} cells pY-STAT1 PTPN2 CD4 Merge ٢ 0 CD4⁺ T_N cells . 0 0 0 CD4⁺ T_{EM} cells n. ar

4


2


0


IL-6

_

е









b

а





d

CD4+

Pattern 1 2 3 4 5

.

STAT1

